China Universal Asset Management Co. Ltd. Grows Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX)

China Universal Asset Management Co. Ltd. raised its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 68.0% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 21,466 shares of the company’s stock after buying an additional 8,685 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Vaxcyte were worth $2,453,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in shares of Vaxcyte by 15.2% in the 1st quarter. Vanguard Group Inc. now owns 9,737,254 shares of the company’s stock worth $665,152,000 after purchasing an additional 1,284,883 shares in the last quarter. RA Capital Management L.P. raised its holdings in Vaxcyte by 4.0% in the first quarter. RA Capital Management L.P. now owns 8,203,754 shares of the company’s stock worth $560,398,000 after buying an additional 312,500 shares during the last quarter. Janus Henderson Group PLC raised its holdings in Vaxcyte by 9.9% in the 1st quarter. Janus Henderson Group PLC now owns 7,673,868 shares of the company’s stock worth $524,117,000 after acquiring an additional 692,492 shares during the last quarter. Capital Research Global Investors lifted its position in Vaxcyte by 20.4% in the 1st quarter. Capital Research Global Investors now owns 4,140,521 shares of the company’s stock valued at $282,839,000 after acquiring an additional 700,414 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in Vaxcyte by 18.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,176,181 shares of the company’s stock valued at $216,966,000 after purchasing an additional 498,359 shares during the last quarter. 96.78% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

PCVX has been the topic of a number of research analyst reports. Leerink Partners upped their price target on Vaxcyte from $106.00 to $153.00 and gave the company an “outperform” rating in a report on Tuesday, September 3rd. Bank of America boosted their price target on Vaxcyte from $101.00 to $140.00 and gave the company a “buy” rating in a report on Wednesday, September 4th. BTIG Research raised their price objective on shares of Vaxcyte from $98.00 to $160.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Jefferies Financial Group boosted their price target on Vaxcyte from $108.00 to $129.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Finally, Mizuho raised their price objective on Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a research report on Tuesday, September 10th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Vaxcyte currently has an average rating of “Buy” and an average price target of $147.50.

Vaxcyte Trading Down 0.1 %

PCVX opened at $112.80 on Tuesday. The firm has a 50 day moving average of $106.76 and a two-hundred day moving average of $84.80. Vaxcyte, Inc. has a 12-month low of $46.16 and a 12-month high of $121.06. The firm has a market capitalization of $12.59 billion, a PE ratio of -24.10 and a beta of 0.99.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($1.10) EPS for the quarter, topping the consensus estimate of ($1.14) by $0.04. During the same quarter in the previous year, the business posted ($0.70) earnings per share. As a group, analysts predict that Vaxcyte, Inc. will post -4.33 EPS for the current fiscal year.

Insiders Place Their Bets

In other Vaxcyte news, CEO Grant Pickering sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $78.98, for a total value of $1,184,700.00. Following the sale, the chief executive officer now owns 478,888 shares of the company’s stock, valued at $37,822,574.24. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Vaxcyte news, CEO Grant Pickering sold 15,000 shares of the stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $78.98, for a total value of $1,184,700.00. Following the sale, the chief executive officer now directly owns 478,888 shares of the company’s stock, valued at approximately $37,822,574.24. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Andrew Guggenhime sold 8,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $115.94, for a total transaction of $927,520.00. Following the sale, the chief financial officer now directly owns 90,383 shares in the company, valued at approximately $10,479,005.02. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 92,098 shares of company stock valued at $9,937,773 over the last ninety days. Company insiders own 3.10% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.